Try-Lean warning letter
This article was originally published in The Tan Sheet
Elroy, Wisc.-based Try-Lean is sent an FDA warning letter Aug. 31 for objectionable claims for its Try-Lean Formula 1 and 2, such as "reduce the risk of heart attack, reduce the risk of cancer, obesity, high blood pressure, ability to kill candida, anti-tumor, anti-bacterial action, wound healing, acne and anti-plaque build-up for dental health." In addition, a Web site and labeling for Calor-Slim make claims for treatment of arthritis, cataracts, glaucoma and diabetic retinopathy. Both products are unapproved new drugs, FDA says
You may also be interested in...
Perrigo promotes in pricing, planning
Combe sells most of its OTC brands
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC